HiberCell doses first patient in phase 1b trial to evaluate HC─7366 in combo with venetoclax and azacitidine to treat ...
HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, announced the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents …